Last reviewed · How we verify
Matrix
At a glance
| Generic name | Matrix |
|---|---|
| Sponsor | Maule Stem Cell Research Institute, Inc. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers (NA)
- Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision (NA)
- Evaluation of Cochlear Implantation in Unilateral or Asymmetric Hearing Loss in Children. (NA)
- Human Repeat Insult Patch Test to Evaluate Skin Irritation and Sensitization in Healthy Volunteers (NA)
- Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease (NA)
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matrix CI brief — competitive landscape report
- Matrix updates RSS · CI watch RSS
- Maule Stem Cell Research Institute, Inc. portfolio CI